These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7516378)

  • 41. [Endocrinological principles of conservative therapy for prostatic adenoma].
    Altwein JE; Orestano F
    Dtsch Med Wochenschr; 1975 Mar; 100(12):626-9. PubMed ID: 47287
    [No Abstract]   [Full Text] [Related]  

  • 42. [Non surgical treatment of benign prostatic hypertrophy: phytotherapy].
    Rizzo M; Del Popolo G; Tosto A
    J Urol (Paris); 1993; 99(6):290-2. PubMed ID: 7516369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study.
    Perimenis P; Gyftopoulos K; Markou S; Barbalias G
    Urology; 2002 Mar; 59(3):373-7. PubMed ID: 11880073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs.
    Habenicht UF; el Etreby MF
    Prostate; 1987; 11(2):133-43. PubMed ID: 2444953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics.
    Matos-Ferreira A; Corte-Real J; Palma J; Durão V
    Br J Urol; 1987 Aug; 60(2):143-9. PubMed ID: 2444307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Influence of gestonoron-capronate (GC) upon uptake and metabolism of H3-testosteron in benign prostatic hypertrophy (BPH): in vivo-experiments (author's transl)].
    Orestano F; Bandhauer K; Altwein JE
    Urologe A; 1974 Nov; 13(6):289-92. PubMed ID: 4141158
    [No Abstract]   [Full Text] [Related]  

  • 48. [Results of treating prostatic adenoma with Depostat].
    Darenkov AF; Zakhvatov IuM; Tanko A; Ignashin NS; Varentsov GI
    Urol Nefrol (Mosk); 1980; (5):34-7. PubMed ID: 6158780
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study.
    Meiraz D; Margolin Y; Lev-Ran A; Lazebnik J
    Urology; 1977 Feb; 9(2):144-8. PubMed ID: 65818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conservative treatment of benign prostatic hyperplasia.
    Palanca E; Juco W
    Curr Med Res Opin; 1977; 4(7):513-20. PubMed ID: 66118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The treatment of benign enlargement of the prostate with nor progesterone caproate (primostat).
    Subbiah N; Mortensen J
    Aust N Z J Surg; 1973 Feb; 42(3):304-7. PubMed ID: 4129814
    [No Abstract]   [Full Text] [Related]  

  • 52. Human benign prostatic hypertrophy: role of prostaglandin E2 and its relationships to bromocriptine therapy.
    Rolland PH; Martin PM; Serment G; Roulier R; Rolland AM
    Eur Urol; 1981; 7(1):41-5. PubMed ID: 6161821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is there a change in the treatment of benign prostatic hyperplasia?
    Altwein JE; Almer F
    Urol Int; 1994; 52(1):1-3. PubMed ID: 7511260
    [No Abstract]   [Full Text] [Related]  

  • 54. [The clinical effects of SH 582 (gestonorone caproate) on benign prostatic hypertrophy].
    Momose S; Hidaka M; Oota Y; Oomaru K
    Hinyokika Kiyo; 1970 Sep; 16(9):551-4. PubMed ID: 4097366
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of benign prostatic hypertrophy with progestogens including gestonorone caproate].
    Nagel R; Hargenda B
    Hinyokika Kiyo; 1970 Sep; 16(9):423-8. PubMed ID: 4097356
    [No Abstract]   [Full Text] [Related]  

  • 56. [Aromatase inhibitors in the medical treatment of benign prostatic hypertrophy].
    Tunn UW; Goldschmidt AJ
    J Urol (Paris); 1993; 99(6):307. PubMed ID: 7516374
    [No Abstract]   [Full Text] [Related]  

  • 57. [Antiestrogens (tamoxifen) in the alternative therapy of benign prostatic hyperplasia].
    Hanus M; Matousková M
    Rozhl Chir; 1993 Oct; 72(7):316-8. PubMed ID: 7508147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of SH 582 (gestonorone caproate) for prostatic hypertrophy].
    Ochiai K; Komase M; Oshima H; Negishi T; Yamauchi A
    Hinyokika Kiyo; 1970 Sep; 16(9):473-81. PubMed ID: 4097359
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of Depostat in prostatic adenoma on the ground of clinical and sphincterotonometric studies.
    Makrigiannis D; Gaca A
    Int Urol Nephrol; 1971; 3(1):21-9. PubMed ID: 4117491
    [No Abstract]   [Full Text] [Related]  

  • 60. [On drug therapy of prostatic hypertrophy].
    Rieben W
    Praxis; 1967 Jul; 56(30):1042-7. PubMed ID: 4180980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.